The exploratory study for the biological effects of metformin on endometrial cancer: effect to cell cycle, MAPK, and AMPK/mTOR signal pathway

The exploratory study for the biological effects of metformin on endometrial cancer: effect to cell cycle, MAPK, and AMPK/mTOR signal pathway - The exploratory study for the effects of metformin on endometrial cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004852

Enrollment

Registered

2011-01-11

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial carcinoma

Interventions

Metformin (an initial dose of 750 mg/day, increased by 750 mg every week up to 1500 or 2250 mg/day) was administered to patients with endometrial cancer prior to surgery. Endometrial tissue was obtai

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Histrogically confirmed grade 1-2 endometrioid adenocarcinoma (2) myometrium invasion was ruled out by MRI (3)performance status of 0 (4) serum creatinine <0.8mg/dl (5) A case without hypersensitivity for this treatment use medicine (6) The case that written informed consent was obtained before participation

Exclusion criteria

Exclusion criteria: (1) The case with a history of the hypersensitivity that is serious for this study use medicine or the drug allergy (2)A history of the lactic acidosis (3)Patients on dialysis (4)Shock, failure heart, myocardial infarction, a cardiovascular injury including the pulmonary embolism (5)Excessive alcohol intake (6)Hepatic dysfunction (7) A history of the thrombosis (8)A case with the psychic disturbance that it seems that we need in the treatment or treatment with antimental medicine (9) Patients with diabetes (10)A case with the double cancer of the activity (11)In addition, the case that the chief physician judged to be inadequate.

Design outcomes

Primary

Measure	Time frame
To evaluate the effects of metformin, cell proliferation activity and signal pathway were compared between pre- and post-treatment samples. 1) Cell proliferation was evaluated by immunohistochemistry using antibody of Ki-67 (positive for all cell cycle except for G0) and topoisomerase II A(positive at S/G2/M phase) 2) Findings related to the MAPK, AMPK and mTOR signaling pathways and cell cycle proteins were compared by Western blot analysis.	—

Measure

Time frame

To evaluate the effects of metformin, cell proliferation activity and signal pathway were compared between pre- and post-treatment samples. 1) Cell proliferation was evaluated by immunohistochemistry using antibody of Ki-67 (positive for all cell cycle except for G0) and topoisomerase II A(positive at S/G2/M phase) 2) Findings related to the MAPK, AMPK and mTOR signaling pathways and cell cycle proteins were compared by Western blot analysis.

—

Secondary

Measure	Time frame
To evaluate the effect for endocrine factors ( HOMA-R, insulin, glucose, leptin, adiponectin) To evaluate the antiproliferative effect of patients serum obtained before and after treatment	—

Countries

Japan

Contacts

Public Contactakira mitsuhashi

Graduate School of Medicine, Chiba University Reproductive Medicine

043-226-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026